Lipophila derivatives of muramylpeptides having properties of activating macrophages and compositions containing them
The invention relates to muramyleptide derivatives resulting essentially from the conjugation or the coupling, as the case may require, through an arm, between a muramylpeptide and a group containing two atoms contiguous with one another to each of which is attached a lipophile chain comprising from 8 to 100 carbon atoms, preferably from 14 to 24 carbon atoms. The derivatives according to the invention are endowed with remarkable stimulating properties with respect to the activation of macrophages, of which they amplify the tumoricidal properties.
Claims
2. The muramylpeptide of claim 1 wherein X is a levogyratory aminoacyl residue or is glycyl.
3. The muramylpeptide of claim 2 wherein X is L-alanyl, L-seryl, L-valyl, L-leucyl, L-isoleucyl, L-threonyl or glycyl.
5. The muramylpeptide of claim 1 wherein R.sub.2 is an alkoxy group.
7. The muramylpeptide of claim 6 wherein R.sub.2 is alkoxy of 1 to 10 carbon atoms and Y is --NH.sub.2.
8. The muramylpeptide of claim 7 wherein R.sub.2 is alkoxy of 4 carbon atoms.
9. The muramylpeptide of claim 8 wherein R.sub.2 is n-butoxy.
10. The muramylpeptide of claim 6 wherein R.sub.3 and R.sub.4 are palmitoyl groups.
12. The muramylpeptide of claim 10 which is 6-O-(beta,gamma-dipalmitoyl-L-glyceryl)-capryl-N-acetyl-muramyl-L-alanyl-D -glutamine-butyl ester.
14. The muramylpeptide of claim 13 wherein R.sub.3 and R.sub.4 are palmitoyl groups.
15. The muramylpeptide of claim 14 which is alpha(N-acetyl-muramyl-L-alanyl-D-isoglutamine), beta, gamma-dipalmitoyl-sn-glycerol.
16. The muramylpeptide of claim 14 which is alpha(N-acetyl-muramyl-D-alanyl-D-isoglutamine), beta, gamma-dipalmitoyl-sn-glycerol.
17. The muramylpeptide of claim 14 which is alpha(N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine), beta, gamma-dipalmitoyl-sn-glycerol.
18. The muramylpeptide of claim 14 which is alpha(N-acetyl-muramyl-D-alanyl-D-isoglutaminyl-L-alanine), beta, gamma-dipalmitoyl-sn-glycerol.
19. A pharmaceutical composition for stimulating the activity of macrophage which comprises a physiologically acceptable carrier and a macrophage stimulant effective amount of said muramylpeptide of claim 1.
20. A method for activating macrophages in a host which comprises the step of: administering to said host a macrophage activating amount said muramylpeptide of claim 1.
21. A method for stimulating anti-infectious activity of macrophages in a host which comprises administering to said host a macrophage stimulating amount of said muramylpeptide of claim 1.
3931139 | January 6, 1976 | Wissmann et al. |
4101536 | July 18, 1978 | Yamamura et al. |
4310514 | January 12, 1982 | Durette |
4315913 | February 16, 1982 | Durette |
4369178 | January 18, 1983 | Yamamura et al. |
4579840 | April 1, 1986 | Hahn |
4628045 | December 9, 1986 | Hahn |
4672106 | June 9, 1987 | Hamaoka et al. |
4681856 | July 21, 1987 | Hamaoka et al. |
4683292 | July 28, 1987 | Hahn |
0025495 | March 1981 | EPX |
0056992 | August 1982 | EPX |
0102319 | October 1984 | EPX |
0135788 | April 1985 | EPX |
- Rose et al., Cancer Treatment Report, vol. 66 No. 1, pp. 135-146, 1982. Long et al., Cancer Treatment Reports, vol. 71, No. 6, pp. 593-598, 1987. Rubin et al., Cancer Treatment Reports, vol. 71, No. 5, pp. 489-492, 1987.
Type: Grant
Filed: Oct 25, 1994
Date of Patent: Dec 30, 1997
Assignee: VACSYN Inc. (Tampa, FL)
Inventors: Nigel Phillips (Pointe Claire), Fran.cedilla.oise Audibert (Neuilly sur Seine), Jean-Marie Bernard (Fontenay le Fleury), Louis Chedid (Paris), Pierre Lefrancier (Gif S/Yvette), Michel Level (Paris), Monique Parant (Paris)
Primary Examiner: Avis M. Davenport
Law Firm: Larson & Taylor
Application Number: 8/329,142
International Classification: A61K 3814; A61K 3816; C07K 900;